ADMA与腹膜透析病人心血管疾病关系的研究进展  

PROGRESSION OF ADMA AND CARDIOVASCULAR DISEASE IN PERITONEAL DIALYSIS PATIENTS

作　　者：张德鱼[1] 赵建荣[2] 

机构地区：[1]内蒙古医学院,内蒙古呼和浩特010059 [2]内蒙古医学院附属医院肾内科

出　　处：《内蒙古医学院学报》2010年第5期508-510,共3页Acta Academiae Medicinae Neimongol

基　　金：内蒙古自治区高等学校科学研究项目基金(NJ10133)

摘　　要：与血液透析(HD)相比,腹膜透析(PD)在某些方面具有血液透析无可比拟的优势,如PD过程中血流动力学比较平稳,体液容量、血生化的起伏波动较小,减少了由于内环境不稳定而产生的透析并发症,如失衡综合症、血压的急剧变化、心律失常及心跳骤停等。但目前很多研究发现心血管疾病仍是导致腹膜透析失败的主要原因,其原因可能与不对称二甲基精氨酸(ADMA)升高所致的内皮功能异常有关。ADMA可作为慢性肾功能不全病人心血管并发症新的预测因子。Compared with hemodialysis （ HD）, peritoneal dialysis （PD） in some aspects has incomparable advantages. Such as during PD, hemodynamic smoothly, humoral capacity, the less blood biochemical fluctuating, reducing the environmental unstable due to the dialysis and complications, such as unbalance syndrome, blood pressure change sharply, arrhythmia and cardiac arrest, etc. But the study found that at present a lot of cardiovascular disease is still leading to peritoneal dialysis failure, and asymmetric dimethylarginine increased leads to endothelial function abnormality. ADMA may be chronic renal insufficiency patients of cardiovascular complications new predictors.

关 键 词：不对称性二甲基精氨酸 腹膜透析 心血管疾病 

分 类 号：R692.5[医药卫生—泌尿科学]